Acesis BioMed is a biomedical company that develops a platform of oral drug candidates for metabolic and endocrine disorders.
Acesis BioMed has raised $1.3M in total funding. The most recent round was Pre-Seed. The last funding was announced in January 2023.
Acesis BioMed's investors include KreaMedica.
Acesis BioMed is headquartered in Denver, United States.
Acesis BioMed is a biomedical company that develops a platform of oral drug candidates for metabolic and endocrine disorders.
Acesis BioMed is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Acesis BioMed — Funding & Investors." VCBacked, January 11, 2023, https://www.vcbacked.co/company/acesis-biomed. Accessed August 14, 2026.
VCBacked. (2023). Acesis BioMed — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/acesis-biomed
{{cite web |title=Acesis BioMed — Funding & Investors |url=https://www.vcbacked.co/company/acesis-biomed |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated